MAPT and amyloidosis: Deleting DAP12 in an amyloid mouse model significantly impairs the formation of microglial barriers around plaques, exacerbating dystrophic neurites bypassing plaques and increasing plaque-associated tau pathology11, while leaving amyloid burden unchanged12.